Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.45 |
| ▸ | CLK2 | P49760 | 5/20 | 0.45 |
| ▸ | CLK1 | P49759 | 3/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.45 |
| ▸ | CLK3 | P49761 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | PRKACA | P17612 | 2/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.39 |
| ▸ | PRKX | P51817 | 2/20 | 0.39 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22440183 | 0.86 | QPCT (0.47) | QPCTGAACDC7DBF4 | |
| SCHEMBL22440204 | 0.83 | CDC7 (0.56) | MAOBCDC7DBF4 | |
| SCHEMBL22440192 | 0.81 | DHFR (0.51) | QPCTMAPK1 | |
| SCHEMBL22440206 | 0.80 | QPCT (0.45) | QPCTDYRK1ACLK4CLK2CLK1 | |
| SCHEMBL21303610 | 0.80 | QPCT (0.47) | QPCTDYRK1ACLK4CLK2CLK1 | |
| SCHEMBL22440185 | 0.79 | MAPT (0.54) | QPCTGAA | |
| SCHEMBL22440207 | 0.78 | MAPT (0.53) | QPCTDYRK1ACLK4CLK1ABL1 | |
| SCHEMBL22440210 | 0.76 | LTA4H (0.52) | DYRK1ACLK4CLK2CLK1DYRK1B | |
| SCHEMBL22440202 | 0.76 | NPC1 (0.43) | DYRK1ACLK1DYRK1BABL1MAPK1 | |
| SCHEMBL22440188 | 0.76 | BRAF (0.40) | QPCTDYRK1ACLK4CLK2CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-04-16 | — | — | US | disclosed |
| US-20200392174-A1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2020-12-17 | — | — | US | disclosed |
| EP-3589632-B1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung Ev (DE) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392174-A1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | GMPS, GLS, QPCT | QPCT 3/4885DYRK1A 4411/4885CLK4 1447/4885 |
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | GMPS, GLS, QPCT | QPCT 3/4885DYRK1A 4459/4885CLK4 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.